# Episode 63. Management of Follicular Lymphoma with Dr. Gilles Salles

Page: https://stenobird.com/podcast/blood-cancer-talks-5570002/episode-63-management-of-follicular-lymphoma-with-dr-gilles-salles
Text version: https://stenobird.com/podcast/blood-cancer-talks-5570002/episode-63-management-of-follicular-lymphoma-with-dr-gilles-salles.md
Podcast: [Blood Cancer Talks](https://stenobird.com/podcast/blood-cancer-talks-5570002)
Published: 2025-07-25T11:53:36+00:00
Episode link: https://share.transistor.fm/s/4fba389f
Audio file: https://media.transistor.fm/4fba389f/25da6735.mp3
Processing state: not_requested
JSON: https://stenobird.com/v1/public/podcasts/blood-cancer-talks-5570002/episodes/episode-63-management-of-follicular-lymphoma-with-dr-gilles-salles
Duration seconds: 3097

## Resource

In this episode, we discuss the management of follicular lymphoma with Dr. Gilles Salles from Memorial Sloan Kettering Cancer Center. Here are the articles we discussed: 1. Relevance of Bone Marrow Biopsy in Follicular Lymphoma: https://pubmed.ncbi.nlm.nih.gov/35787017/ 2. TROG 99.03 (RCT of Systemic Therapy after Involved-Field Radiotherapy in Patients with Early-Stage Follicular Lymphoma): https://pubmed.ncbi.nlm.nih.gov/29975623/ 3. Long-term follow-up results of RCT comparing early rituximab monotherapy versus watchful waiting for advanced stage, asymptomatic, low tumor burden follicular lymphoma: https://pubmed.ncbi.nlm.nih.gov/40306831/ 4. RELEVANCE RCT: Lenalidomide plus Rituximab (R2) Versus Rituximab-Chemotherapy Followed by Rituximab Maintenance in Untreated Advanced Follicular Lymphoma: https://ascopubs.org/doi/10.1200/JCO.22.00843 5. GALLIUM RCT: Obinutuzumab Versus Rituximab Immunochemotherapy in Previously Untreated iNHL. https://pubmed.ncbi.nlm.nih.gov/37404773/ https://pubmed.ncbi.nlm.nih.gov/28976863/ 6. Long-term follow-up of mosunetuzumab in relapsed/refractory FL: https://pubmed.ncbi.nlm.nih.gov/39447094/ 7. Epcoritamab in relapsed/refractory FL: https://pubmed.ncbi.nlm.nih.gov/38889737/ 8. Phase 3 inMIND RCT: Tafasitamab plus Lenalidomide and Rituximab for Relapsed or Refractory Follicular Lymphoma: https://ashpublications.org/blood/article/144/Supplement%202/LBA-1/534319 9. Long term follow-up results from the Phase 3 PRIMA trial of rituximab maintenance in Follicular Lymphoma: https://ascopubs.org/doi/10.1200/JCO.19.01073

## Actions

- request_transcript: `POST https://stenobird.com/v1/public/podcasts/blood-cancer-talks-5570002/episodes/episode-63-management-of-follicular-lymphoma-with-dr-gilles-salles/transcription-requests` — Idempotently request low-priority transcript generation for this episode.
- read_markdown: `GET https://stenobird.com/podcast/blood-cancer-talks-5570002/episode-63-management-of-follicular-lymphoma-with-dr-gilles-salles.md` — Read the agent-friendly Markdown representation of this episode resource.

A page view does not enqueue transcription. Agents should invoke `request_transcript` explicitly when they need this episode processed.

## Transcript

Full transcripts are not published on public pages unless there is a clear rights basis.